KAUST Team Inserts Large Genes Precisely Into Plant Genomes, While Alzheimer's Research Opens a Non-Amyloid Path

Two unrelated but headline-grabbing biomedical results landed this week. A team at King Abdullah University of Science and Technology (KAUST) published a genome-engineering method that places large functional genes at precise spots in plant genomes - validated in tobacco and rice. Separately, an Alzheimer's study showed cognitive restoration in animal models through a mechanism that does not require clearing amyloid plaques.

KAUST's Plant Genome Tool

The new method, published in Nature Biotechnology, sidesteps a long-standing bottleneck: precise insertion of DNA fragments larger than about 5 kilobases. Existing tools work well for small edits but struggle with full metabolic pathways or multi-gene cassettes.

"We can now drop a 15-kilobase pathway into a known safe-harbor site in rice, with the kind of precision we used to get only for single genes," said Magdy Mahfouz, who led the KAUST team.

How It Works

• Prime editor anchor: a guide-RNA points the integration machinery at a specific genomic address
• Donor assembly: large inserts are delivered as preassembled DNA rather than built inside the cell
• Selection-free genotyping: PCR-based screening eliminates the need for marker genes

The method has immediate applications in biofortification, stress tolerance, and metabolic engineering of staple crops. Mahfouz's group is now partnering with international rice and cassava programs to deploy it in smallholder-relevant varieties.

An Alzheimer's Off-Ramp From Amyloid

The Alzheimer's result, published in Neuron and covered by ScienceDaily, attacks the disease without touching amyloid-β plaques - the target of nearly every late-stage Alzheimer's drug. Instead, the therapy restores function in cellular waste-clearance pathways downstream of plaque deposition.

In mouse models, treated animals showed measurable improvements in spatial memory and synaptic plasticity within weeks. Two-hour windows of enhanced slow-wave sleep - already known to correlate with glymphatic clearance - appear to mediate the effect.

"We are not arguing amyloid doesn't matter. We are saying there are other treatable pathways, and they may be faster to drug," said the study's lead author.

Why Both Matter

Both results illustrate a theme: precision and resilience. KAUST's tool gives plant biologists a more precise way to engineer crops without dragging along marker genes. The Alzheimer's work gives patients a plausible mechanism that does not depend on a 30-year-old target that has repeatedly disappointed in late-stage trials.

Clinical trials of the Alzheimer's approach are being designed for 2027.